Inhibitor Therapeutics, Inc. (INTI) Stock Price & Analysis
Inhibitor Therapeutics, Inc. (INTI) rose 20.27% to USD 0.09 as of September 8, 2026 at 21:55 UTC, according to Nexqual real-time market data.
INTI last closed at USD 0.07; the session ranged USD 0.09–0.09 on volume of 1,000 shares. Market capitalization is $15.56M, with a 52-week range of USD 0.04–0.12 (OQB). Source: Nexqual, September 8, 2026 at 21:55 UTC.
Key Statistics (as of September 8, 2026 at 21:55 UTC)
| Price | USD 0.09 |
|---|---|
| Change | ▲ 20.27% (up) |
| Previous Close | USD 0.07 |
| Open | USD 0.09 |
| Day Range | USD 0.09 – 0.09 |
| 52-Week Range | USD 0.04 – 0.12 |
| Volume | 1,000 shares |
| Market Cap | $15.56M |
| Exchange | OQB |
Technical Analysis (INTI)
Nexqual's technical model rates INTI "STRONG SELL" based on 0 bullish and 5 bearish signals across 126 daily candles, as of September 8, 2026 at 21:55 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 43.98 (neutral) |
| vs SMA50 | Above (USD 0.08) |
| MACD | -0 (negative) |
Analyst Ratings (INTI)
Wall Street analysts rate INTI "None", per Nexqual as of September 8, 2026 at 21:55 UTC.
| Consensus Rating | None |
|---|
Financial Health Score (INTI)
Nexqual rates Inhibitor Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 21:55 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $516K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$3M |
| Efficiency | Mixed — No data |
Leadership (INTI)
Inhibitor Therapeutics, Inc. is led by Francis E. O'Donnell Jr. (age 75), Founder, Executive Chairman & CEO, per Nexqual as of September 8, 2026 at 21:55 UTC.
| Founder, Executive Chairman & CEO | Francis E. O'Donnell Jr. (age 75) |
|---|---|
| Interim CFO, Treasurer & Secretary | James A. McNulty (age 75) |
From Inhibitor Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States.
- It engages in the development of therapies initially for basal cell carcinoma nevus syndrome (BCCNS) cancers by utilizing itraconazole; development of therapies initially for basal cell carcinoma (BCC) cancers; and SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CLRN | CLARENT CORP | USD 0 | ▲ 0% |
| ATGN | Altigen Communications, Inc. | USD 0.5 | ▼ 1% |
| MWAI | MedwellAI, Inc. | USD 0.37 | ▲ 0% |
| CLST | Catalyst Bancorp, Inc. | USD 18.15 | ▲ 3.63% |
| ASPT | ALADDIN SEPARATION TECHNOLOGIES | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 21:55 UTC. This page is informational and not investment advice.